Read E.V.I.dently Today for current news about health policy and events, among other topics.
E.V.I.dently Today Blog
Acceptance of studies based on “real-world data” remains limited, partly because the research methods used to generate usable evidence are not always transparent. That perception could change thanks to new efforts by the National Pharmaceutical Council and AcademyHealth aimed at improving the credibility and reliability of real-world evidence.
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care spending, rather than zeroing in on a single aspect of the health care system. The implications, he notes, are that “focusing only on the costs of a few innovative treatments doesn’t enable us to take a step back and see the bigger picture,” and that could have significant implications for health policy decisions.
This week, the Institute for Clinical and Economic Review (ICER) has announced that it is planning to revise its value assessment framework process. In a perfect world, every framework developer would follow guiding practices to ensure they are using sound methodology and evidence, meaningfully incorporating patient input, and considering a broad array of benefits and costs over a longer timeframe, as outlined in NPC's "Guiding Practices for Patient-centered Value Assessment" and highlighted in this blog post.
In Louisiana, significant prevalence of hepatitis C cases and high treatment costs has led the state to turn to an innovative idea – using a Netflix-style subscription model to pay for curative hepatitis C medicines, in which the state will be able to access all the hepatitis C medicines it needs under a fixed cost, five-year contract. This unique payment model will be a central part of a pre-conference symposium at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in New Orleans on Sunday, May 19 at 5:30 p.m. CT. The pre-conference symposium, sponsored by NPC, is open to all registered meeting attendees.
Loud and Clear: Key Takeaways from a Webinar on “Amplifying the Patient Voice” in Quality Measurement
In a Feb. 28 webinar from NPC and Discern Health, a group of diverse speakers discussed policy solutions for improving patient-reported measures in oncology value-based programs, along with a white paper on the topic.
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over utilization and sickness.